Your browser is no longer supported. Please, upgrade your browser.
ObsEva SA
Index- P/E- EPS (ttm)-1.49 Insider Own6.80% Shs Outstand68.57M Perf Week2.02%
Market Cap149.76M Forward P/E- EPS next Y-0.70 Insider Trans0.00% Shs Float36.78M Perf Month-16.83%
Income-81.10M PEG- EPS next Q-0.26 Inst Own38.10% Short Float1.94% Perf Quarter-19.49%
Sales0.02M P/S7882.29 EPS this Y33.10% Inst Trans0.01% Short Ratio0.39 Perf Half Y-29.61%
Book/sh0.72 P/B3.50 EPS next Y30.70% ROA-98.10% Target Price- Perf Year-3.82%
Cash/sh1.14 P/C2.20 EPS next 5Y- ROE-312.90% 52W Range1.86 - 5.55 Perf YTD21.15%
Dividend- P/FCF- EPS past 5Y-20.00% ROI- 52W High-54.59% Beta0.76
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin- 52W Low35.85% ATR0.18
Employees45 Current Ratio4.30 Sales Q/Q50.00% Oper. Margin- RSI (14)41.19 Volatility11.26% 5.96%
OptionableYes Debt/Eq0.54 EPS Q/Q39.00% Profit Margin- Rel Volume0.88 Prev Close2.59
ShortableYes LT Debt/Eq0.53 Earnings- Payout- Avg Volume1.82M Price2.52
Recom1.30 SMA20-6.75% SMA50-12.00% SMA200-12.14% Volume1,594,729 Change-2.70%
Nov-09-20Downgrade JP Morgan Neutral → Underweight
Jul-07-20Downgrade JP Morgan Overweight → Neutral $18 → $5
Jul-07-20Downgrade BMO Capital Markets Outperform → Market Perform $5 → $4
Nov-08-19Downgrade Credit Suisse Outperform → Neutral $16 → $4
Sep-13-18Initiated JP Morgan Overweight $29
Aug-15-18Resumed Leerink Partners Outperform $25
Aug-07-18Initiated Wedbush Outperform $34
Jul-19-18Initiated Credit Suisse Outperform $24
Oct-11-17Reiterated H.C. Wainwright Buy $27 → $25
Sep-15-17Initiated RBC Capital Mkts Outperform $22
Aug-16-17Resumed Leerink Partners Outperform $18
Jun-29-17Initiated H.C. Wainwright Buy $27
Feb-21-17Initiated Leerink Partners Outperform $21
Feb-21-17Initiated Jefferies Buy $21
Feb-21-17Initiated Credit Suisse Outperform $27
Jul-27-21 06:26AM  
Jul-12-21 08:44AM  
Jul-02-21 01:00AM  
Jun-30-21 01:00AM  
Jun-24-21 01:00AM  
Jun-14-21 07:01PM  
Jun-10-21 01:00AM  
Jun-02-21 01:00AM  
May-31-21 01:00AM  
May-25-21 04:05PM  
May-20-21 06:25AM  
May-17-21 10:40AM  
May-06-21 01:00AM  
May-04-21 01:00AM  
Apr-30-21 04:05PM  
Apr-27-21 09:12AM  
Apr-22-21 01:00AM  
Mar-05-21 01:00AM  
Mar-03-21 01:00AM  
Feb-18-21 11:15AM  
Feb-17-21 01:00AM  
Feb-15-21 02:51AM  
Feb-11-21 01:00AM  
Feb-10-21 01:00AM  
Jan-28-21 01:00AM  
Jan-19-21 08:58AM  
Jan-15-21 11:45AM  
Jan-11-21 01:00AM  
Jan-07-21 01:00AM  
Jan-04-21 01:00AM  
Dec-10-20 01:00AM  
Dec-02-20 02:37PM  
Dec-01-20 01:00AM  
Nov-30-20 08:48AM  
Nov-24-20 08:12AM  
Nov-16-20 02:08AM  
Nov-13-20 01:00AM  
Nov-09-20 01:00AM  
Nov-05-20 01:00AM  
Nov-02-20 01:00AM  
Oct-22-20 01:00AM  
Oct-20-20 01:00AM  
Oct-06-20 03:30PM  
Sep-08-20 01:00AM  
Sep-03-20 05:00PM  
Aug-07-20 01:00AM  
Aug-06-20 01:00AM  
Jul-23-20 05:55AM  
Jul-15-20 01:00AM  
Jul-06-20 08:08AM  
Jul-03-20 01:00AM  
Jul-01-20 01:00AM  
Jun-29-20 01:00AM  
Jun-21-20 10:40PM  
Jun-09-20 04:01PM  
Jun-04-20 08:13AM  
May-29-20 01:00AM  
May-11-20 07:55AM  
May-08-20 04:30PM  
May-07-20 09:30AM  
May-05-20 04:34AM  
Apr-23-20 08:45AM  
Apr-22-20 04:30PM  
Apr-21-20 09:02AM  
Apr-14-20 01:00AM  
Apr-06-20 01:00AM  
Mar-27-20 02:00AM  
Mar-23-20 02:00AM  
Mar-05-20 04:43AM  
Feb-27-20 01:00AM  
Feb-18-20 01:00AM  
Jan-22-20 09:34AM  
Jan-16-20 11:27AM  
Jan-15-20 01:00AM  
Jan-13-20 01:00AM  
Jan-09-20 04:09PM  
Jan-07-20 01:00AM  
Dec-16-19 06:10AM  
Dec-12-19 04:11PM  
Dec-09-19 11:53AM  
Dec-06-19 04:30PM  
Dec-03-19 06:49AM  
Nov-18-19 02:44PM  
Nov-15-19 10:47AM  
Nov-08-19 08:14AM  
Nov-07-19 07:30AM  
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.